{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.Clinicalstudies.in/SOP-for-Follow-Up-and-Closure-of-Monitoring-Findings”
},
“headline”: “SOP for Follow-Up and Closure of Monitoring Findings”,
“description”: “This SOP defines procedures for the follow-up and closure of monitoring findings in clinical trials, ensuring timely CAPA implementation, documentation, and compliance with FDA, EMA, CDSCO, WHO, and ICH GCP requirements.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Follow-Up and Closure of Monitoring Findings

Purpose

The purpose of this SOP is to describe the standardized process for follow-up and closure of monitoring findings identified during clinical trial monitoring visits. This ensures that deviations, deficiencies, and non-compliance are corrected, preventive actions are taken, and all activities are fully documented for inspection readiness.

Scope

This SOP applies to CRAs, investigators, sponsors, CROs, study coordinators, and QA officers responsible for monitoring follow-up and CAPA management. It covers findings from onsite, remote, and central monitoring activities, including deviations, informed consent deficiencies, drug accountability issues, data entry delays, and protocol compliance concerns.

Responsibilities

• CRA/Monitor: Tracks findings, ensures CAPA is implemented, and documents closure.
• PI: Implements corrective actions at site level and provides CAPA responses.
• Study Coordinator: Assists PI in executing corrective measures and submitting evidence.
• Clinical Operations Manager: Oversees CAPA timelines and verifies resolution adequacy.
• Sponsor/CRO: Ensures follow-up findings are closed and reported per regulatory timelines.
• QA Officer: Reviews closed findings, verifies CAPA documentation, and audits process for compliance.

Accountability

The sponsor is accountable for ensuring all monitoring findings are addressed and closed. The CRA is accountable for documenting follow-up, while the PI is accountable for implementing corrective actions at site level.

Procedure

1. Identification of Findings
Document findings in Monitoring Visit Report (MVR).
Categorize findings as Critical, Major, or Minor.
Share findings with site PI within 10 working days.

2. CAPA Development
PI/site staff develop CAPA plan for each finding within 15 working days.
CAPA plan must address root cause, corrective action, and preventive action.
Submit CAPA plan to CRA and sponsor for review.

3. CAPA Implementation
Site executes corrective actions (e.g., retraining staff, updating records, revising procedures).
CRA verifies implementation during follow-up visit or remote review.
Record updates in CAPA Log (Annexure-1).

4. Documentation of Evidence
PI provides evidence of corrective actions (signed logs, updated consent forms, reconciliation reports).
CRA ensures all evidence is filed in TMF/ISF.

5. Closure Verification
CRA confirms CAPA effectiveness and documents closure in Finding Closure Log (Annexure-2).
Clinical Operations Manager approves closure.
QA performs independent review for selected findings.

6. Timelines
CAPA submission: within 15 working days of receiving MVR.
CRA follow-up verification: within 30 working days.
Closure approval: within 45 working days.

7. Escalation
If CAPA is not implemented or ineffective, escalate to sponsor immediately.
Document in Escalation Log (Annexure-3).

8. Archiving
Archive CAPA logs, closure documentation, and escalation records in TMF.
Retain for at least 15 years or per local regulations.

Abbreviations

• SOP: Standard Operating Procedure
• PI: Principal Investigator
• CRA: Clinical Research Associate
• CRO: Clinical Research Organization
• QA: Quality Assurance
• TMF: Trial Master File
• ISF: Investigator Site File
• CAPA: Corrective and Preventive Action
• MVR: Monitoring Visit Report

Documents

1. CAPA Log (Annexure-1)
2. Finding Closure Log (Annexure-2)
3. Escalation Log (Annexure-3)

References

• ICH E6(R2) – Good Clinical Practice
• FDA – Guidance on Risk-Based Monitoring
• EMA – Monitoring and CAPA Management
• CDSCO – Monitoring and CAPA Requirements
• WHO – Monitoring Follow-Up Guidance

Version: 1.0

Approval Section

Annexures

Annexure-1: CAPA Log

Annexure-2: Finding Closure Log

Annexure-3: Escalation Log

Revision History

For more SOPs visit: Pharma SOP

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.Clinicalstudies.in/SOP-for-Monitoring-Plan-Development-RBM-Enabled”
},
“headline”: “SOP for Monitoring Plan Development (Risk-Based Monitoring Enabled)”,
“description”: “This SOP defines procedures for developing a monitoring plan with risk-based monitoring (RBM) strategies in clinical trials. It ensures compliance with FDA, EMA, CDSCO, WHO, and ICH GCP expectations for adaptive, data-driven trial oversight.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Monitoring Plan Development (RBM Enabled)

Purpose

The purpose of this SOP is to define the process for developing a monitoring plan in clinical trials, with emphasis on Risk-Based Monitoring (RBM). The monitoring plan provides a structured approach to ensure subject safety, data integrity, and compliance with regulatory requirements, while optimizing monitoring resources through a risk-based strategy.

Scope

This SOP applies to sponsors, CROs, clinical research associates (CRAs), monitors, and investigators involved in planning and executing clinical trial monitoring activities. It covers development of a monitoring strategy, RBM methodology, central monitoring integration, onsite and remote monitoring schedules, escalation procedures, and documentation requirements.

Responsibilities

• Sponsor: Oversees monitoring plan design, approval, and compliance with regulatory requirements.
• Clinical Operations Manager: Develops monitoring strategy, incorporating RBM principles.
• CRA/Monitor: Executes monitoring plan, documents findings, and ensures corrective actions.
• Data Manager: Provides risk metrics and key risk indicators (KRIs) for RBM integration.
• Principal Investigator (PI): Ensures site compliance and facilitates monitoring visits.
• QA Officer: Audits monitoring plans and verifies adherence during inspections.

Accountability

The sponsor is accountable for ensuring that a comprehensive monitoring plan is developed, risk-based elements are integrated, and monitoring activities are aligned with regulatory expectations (ICH GCP E6 R2, FDA guidance, EMA RBM reflection paper).

Procedure

1. Risk Assessment
Conduct trial-level risk assessment before drafting the monitoring plan.
Identify critical data and processes impacting subject safety and data integrity.
Define Key Risk Indicators (KRIs) such as SAE reporting timelines, data entry lag, and protocol deviations.

2. Monitoring Strategy Development
Choose appropriate monitoring model: 100% SDV, targeted SDV, centralized monitoring, or hybrid.
Document rationale for selected strategy in the Monitoring Strategy Log (Annexure-1).

3. RBM Methodology Integration
Incorporate centralized data review dashboards for trend analysis.
Use KRIs and Quality Tolerance Limits (QTLs) to guide monitoring intensity.
Trigger escalations when KRIs exceed predefined thresholds.

4. Monitoring Visit Planning
Define frequency of onsite and remote visits based on risk profile.
Schedule visits proportionally to enrollment, data volume, and site history.
Record planned visits in Monitoring Visit Schedule (Annexure-2).

5. Monitoring Tools and Templates
Use standardized checklists and monitoring report templates.
Ensure all tools are stored in TMF for inspection readiness.

6. Execution and Documentation
CRAs execute visits, review source data, verify CRF entries, and assess protocol compliance.
Findings are documented in Monitoring Visit Reports (Annexure-3).
Serious issues must be escalated to Clinical Operations Manager within 24 hours.

7. Escalation and CAPA
Escalate major protocol deviations, repeated non-compliance, or GCP violations.
CAPA plans must be developed, implemented, and tracked.
Document escalations in Escalation Log (Annexure-4).

8. Review and Updates
Monitoring plan must be reviewed at least annually or when significant protocol changes occur.
Updates must be version controlled and filed in TMF.

9. Archiving
Archive final monitoring plans, reports, logs, and escalations for at least 15 years.
Maintain retrievability for regulatory inspections.

Abbreviations

• SOP: Standard Operating Procedure
• PI: Principal Investigator
• CRA: Clinical Research Associate
• CRO: Clinical Research Organization
• QA: Quality Assurance
• TMF: Trial Master File
• ISF: Investigator Site File
• RBM: Risk-Based Monitoring
• KRI: Key Risk Indicator
• QTL: Quality Tolerance Limit
• SDV: Source Data Verification

Documents

1. Monitoring Strategy Log (Annexure-1)
2. Monitoring Visit Schedule (Annexure-2)
3. Monitoring Visit Report (Annexure-3)
4. Escalation Log (Annexure-4)

References

• ICH E6(R2) – Good Clinical Practice
• FDA – Guidance on Risk-Based Monitoring
• EMA – Risk-Based Quality Management in Clinical Trials
• CDSCO – Monitoring Requirements for Clinical Trials
• WHO – Monitoring Guidelines in Clinical Research

Version: 1.0

Approval Section

Annexures

Annexure-1: Monitoring Strategy Log

Annexure-2: Monitoring Visit Schedule

Annexure-3: Monitoring Visit Report

Annexure-4: Escalation Log

Revision History

For more SOPs visit: Pharma SOP